• DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Parasitic worms
      • Mycetoma
      • Dengue
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Evidence for impact
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi West and Central Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • Our story
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Parasitic worms
      • Mycetoma
      • Dengue
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Evidence for impact
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi West and Central Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • Our story
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > News

DNDi delivers statement about CEWG on R&D Financing and Coordination at 69th World Health Assembly

Home > News

DNDi delivers statement about CEWG on R&D Financing and Coordination at 69th World Health Assembly

World Health Assembly 2016
27 May 2016

At the 69th World Health Assembly, Member States were asked to consider the outcomes of the Open-Ended Meeting and continue discussions on issues related to monitoring, coordination and financing for health research.

Michelle Childs, DNDi‘s Head of Policy Advocacy, delivered the following statement on behalf of DNDi.

“The main system driving and financing medical innovation is failing to deliver on many fronts. R&D is lacking for Neglected Tropical Diseases, emerging infectious diseases, antimicrobial resistance; Access to Hepatitis treatment is rationed.

DNDi’s portfolio has expanded beyond an NTD focus (including the demonstration project for leishmaniasis) to reflect this.

Innovation and access are on the political agenda like never before, but the response to these failures is fragmented. At this assembly multiple agenda items propose R&D frameworks.

Different frameworks for different diseases fail to address 5  core problems:

  1. No global body to identify R&D needs,
  2. No globally-agreed priority setting,
  3. No coordination of R&D efforts to reduce duplication,
  4. Lack of sustainable financing,
  5. No globally-agreed norms that guide R&D initiatives to ensure affordability

This agenda item presents an opportunity to consider a common core framework and the elements within it.

DNDi’s model is based on open innovation, de-linkage, and affordable access. Based on our experience, we urge Member States to consider 4 actions to enable the emergence of a more sustainable and efficient innovation system:

  1. Request WHO to establish a process for priority setting for all areas of public health importance;
  2. ensure the Global Observatory is sustainably funded and covers all areas of public health importance;
  3. ensure pooled funds cover all areas of need, focus on agreed priorities and apply the CEWG principles of innovation with access including de-linkage;
  4. join the dots between multiple frameworks and progressively  develop an overarching framework for all R&D actors and all areas of public health importance.  Including  WHO  engaging  in other policy fora to promote the implementation of the CEWG principles.

Member States should ask WHO to organize an intergovernmental conference on policy coherence for R&D, to consider core common elements for development of global frameworks for R&D.”

Read, watch, share

Loading...
Statements
25 Sep 2026

DNDi intervention at the UN High-Level Meeting on Pandemic Prevention, Preparedness, and Response at the 81st UN General Assembly

Viewpoints
30 Sep 2030

How a one-day cure could finally eliminate sleeping sickness in Africa

News
15 Sep 2026

New DNDi report: Implementing Article 9.5 of the WHO Pandemic Agreement – building on current policy and practice for publicly funded R&D

Hand with lap glove holding a sample with transparent liquid
Publications
8 Sep 2026

Implementing Article 9.5 of the WHO Pandemic Agreement

Stories
27 Aug 2026

Drug discovery explained: Moonshot: open science to prepare for pandemics?

Pictures of patients waiting at the Mycetoma Research Center in Sudan
Stories
20 Aug 2026

Mycetoma at 10: What recognition made possible

Nature Africa logo
Viewpoints
3 Aug 2026

A new chapter for African medical innovation

Nature Africa
Viewpoints
30 Jul 2026

Ten years after WHO recognition, mycetoma remains one of the world’s most neglected diseases

Stat News
VIEW ALL

Help neglected patients

To date, we have delivered seventeen new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
Linkedin-in Instagram Youtube Tiktok Facebook-f
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films, and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International license